AR054031A1 - Compuestos acilaminobiciclicos ligandos de receptores cannabinoides - Google Patents
Compuestos acilaminobiciclicos ligandos de receptores cannabinoidesInfo
- Publication number
- AR054031A1 AR054031A1 ARP060101523A ARP060101523A AR054031A1 AR 054031 A1 AR054031 A1 AR 054031A1 AR P060101523 A ARP060101523 A AR P060101523A AR P060101523 A ARP060101523 A AR P060101523A AR 054031 A1 AR054031 A1 AR 054031A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- alkoxy
- halogen
- aryl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 102000018208 Cannabinoid Receptor Human genes 0.000 title 1
- 108050007331 Cannabinoid receptor Proteins 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 7
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Chemical group 0.000 abstract 5
- 229910052760 oxygen Inorganic materials 0.000 abstract 5
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 150000003951 lactams Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000001424 substituent group Chemical group 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- -1 C1-4 alkyl-SO2- Chemical group 0.000 abstract 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 150000002596 lactones Chemical class 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
Abstract
Composiciones farmacéuticas que los contienen y uso como agentes antiinflamatorios. Reivindicacion 1: Un compuesto de formula (1) en la que R1 y R2 son cada uno de forma independiente un arilo sustituido opcionalmente con uno o más sustituyentes, o un heteroarilo sustituido opcionalmente con uno o más sustituyentes; V es O y W es CR3aR3b, o V es CR3aR3b y W es N-R4; R3a, R3b, R5a, R5b, R6a, R6b, y R7a son cada uno de forma independiente H, alquilo C1-4, o alquilo C1-4 sustituido con halogeno; R4 es H, alquilo C1-4, alquilo C1-4 sustituido con alogeno, (alcoxi C1-4)-C(O)-, arilo, (alquil C1-4)-C(O)-, (aril)-C(O)-, (alquil C1-4)-SO2-, o (aril)-SO2-; R7b es (i) H, (ii) alquilo C1-6, (iii) alquenilo C2-6, (iv) alquilo C1-4 sustituido con halogeno, (v) -C(O)-(CH2)pR8, en el que p es 0 o 1, y R8 es un resto químico seleccionado del grupo que consiste en alquilo C1-6, alquenilo C2-6, alcoxi C1-4, cicloalquilo C3-7, alquil C1-4-SO2-, heterociclo de 3 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados de forma independiente entre O, N y S, lactama o lactona de 5 a 6 miembros y heteroarilo de 5 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados de forma independiente entre O, N y S, en el que dicho resto químico se encuentra opcionalmente sustituido con uno o más sustituyentes seleccionados entre alquilo C1-4, alcoxi C1-4, trifluorometilo, halo, ciano, amino, alquil C1-4-amino, o di-alquil C1-4-amino; o R8 considerado junto con R7a forman una lactama de 5 a 6 miembros; (vi) -C(O)-O-R9, en el que R9 es alquilo C1-6, alquilo C1-6 sustituido con halogeno o alcoxi C1-4-alquilo C1-6; o R9 considerado junto con R7a forman una lactona de 5 a 6 miembros, o (vii) -C(O)-N(R10a)(R10b) en el que R10a es H, alquilo C1-6, o alquilo C1-4 sustituido con halogeno, y R10b es H, alquilo C1-6, alquilo C1-4 sustituido con halogeno, alquenilo C2-6, cicloalquilo C3-7, heterociclo de 3 a 6 miembros que contiene de 1 a 3 heteroátomos seleccionados de forma independiente entre O, N y S, lactama o lactona de5 a 6 miembros, y heteroarilo de 5 a 6 miembros que contiene de uno a tres heteroátomos seleccionados de forma independiente entre O, N y S, en el que dicho resto químico se encentra sustituido opcionalmente con uno o más sustituyentes seleccionados entre alquilo C1-4, alcoxi C1-4, trifluorometilo, halo, ciano, amino, alquil C1-4-amino, o di-alquil C1-4-amino, o R10a y R10b considerados conjuntamente forman una piperidina o una pirrolidina, o bien R10a o R10b considerados conjuntamente con R7a forman una lactama de 5 a 6 miembros; o una sal farmacéuticamente aceptable del mismo, o un solvato o hidrato del compuesto o de la sal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US67354605P | 2005-04-20 | 2005-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR054031A1 true AR054031A1 (es) | 2007-05-30 |
Family
ID=36691573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060101523A AR054031A1 (es) | 2005-04-20 | 2006-04-18 | Compuestos acilaminobiciclicos ligandos de receptores cannabinoides |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20060241100A1 (es) |
| EP (1) | EP1874779A1 (es) |
| JP (1) | JP2008536909A (es) |
| AR (1) | AR054031A1 (es) |
| CA (1) | CA2605479A1 (es) |
| DO (1) | DOP2006000087A (es) |
| GT (1) | GT200600156A (es) |
| NL (1) | NL1031627C2 (es) |
| PE (1) | PE20061315A1 (es) |
| TW (1) | TW200714603A (es) |
| UY (1) | UY29478A1 (es) |
| WO (1) | WO2006111849A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20090062253A1 (en) * | 2007-08-31 | 2009-03-05 | Kalypsys, Inc. | Heterocyclodiazepine cannabinoid receptor modulators for treatment of disease |
| US8470841B2 (en) | 2008-07-09 | 2013-06-25 | Sanofi | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| ES2443016T3 (es) | 2009-08-26 | 2014-02-17 | Sanofi | Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo |
| EP2582709B1 (de) | 2010-06-18 | 2018-01-24 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US20240189287A1 (en) * | 2021-03-12 | 2024-06-13 | Bionanosim (Bns) Ltd | Peripherally restricted cb1 receptor blockers and uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7129239B2 (en) * | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
| US20040214856A1 (en) * | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| US7232823B2 (en) * | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
| US7151097B2 (en) * | 2003-11-07 | 2006-12-19 | Pfizer Inc. | Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
-
2006
- 2006-04-10 WO PCT/IB2006/001021 patent/WO2006111849A1/en not_active Ceased
- 2006-04-10 EP EP06744571A patent/EP1874779A1/en not_active Withdrawn
- 2006-04-10 JP JP2008507192A patent/JP2008536909A/ja active Pending
- 2006-04-10 CA CA002605479A patent/CA2605479A1/en not_active Abandoned
- 2006-04-11 DO DO2006000087A patent/DOP2006000087A/es unknown
- 2006-04-18 UY UY29478A patent/UY29478A1/es not_active Application Discontinuation
- 2006-04-18 AR ARP060101523A patent/AR054031A1/es unknown
- 2006-04-18 PE PE2006000403A patent/PE20061315A1/es not_active Application Discontinuation
- 2006-04-19 NL NL1031627A patent/NL1031627C2/nl not_active IP Right Cessation
- 2006-04-19 GT GT200600156A patent/GT200600156A/es unknown
- 2006-04-19 TW TW095113918A patent/TW200714603A/zh unknown
- 2006-04-20 US US11/409,458 patent/US20060241100A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| GT200600156A (es) | 2006-11-22 |
| NL1031627C2 (nl) | 2007-07-10 |
| CA2605479A1 (en) | 2006-10-26 |
| TW200714603A (en) | 2007-04-16 |
| EP1874779A1 (en) | 2008-01-09 |
| NL1031627A1 (nl) | 2006-10-23 |
| WO2006111849A1 (en) | 2006-10-26 |
| JP2008536909A (ja) | 2008-09-11 |
| DOP2006000087A (es) | 2006-10-31 |
| PE20061315A1 (es) | 2007-01-13 |
| UY29478A1 (es) | 2006-11-30 |
| US20060241100A1 (en) | 2006-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR054031A1 (es) | Compuestos acilaminobiciclicos ligandos de receptores cannabinoides | |
| AR055150A1 (es) | Compuestos de isoindol - imido y composiciones que los comprenden y sus metodos de uso | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| AR052943A1 (es) | Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida | |
| AR057984A1 (es) | DERIVADOS DE IMIDAZOL INHIBIDORES DE LA PROTEINA beta AMILOIDE | |
| ES2640911T3 (es) | Cicloalquilnitrilpirazolcarboxamidas como inhibidores de la quinasa Janus | |
| CO5700780A2 (es) | Derivados de quinolina como inhibidores, selectivos, de de fosfodiesterasa pde 4b | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| AR051202A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR048376A1 (es) | C- glicosidos heterociclos fusionados sustituidos | |
| AR044539A1 (es) | Ligandos de receptores de canabinoides y sus usos | |
| AR051092A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa | |
| NO20063380L (no) | Triazolderivater som vasopressinantagonister | |
| CO5700754A2 (es) | Derivados de piperazina y su uso en el tratamiento de enfermedades neurologicas y psiquiatricas | |
| ECSP055974A (es) | Síntesis de cloruros de 4 amino-2-butenoil y su uso en la preparación de 3-ciano quinolinas | |
| AR044011A1 (es) | Antagonistas de mchr1 heterociclicos | |
| AR074504A1 (es) | Nucleotidos uracil ciclopropilicos | |
| AR057989A1 (es) | Derivados de indol-2-il-amida 1,5-sustituida. procesos de obtencion y composiciones farmaceuticas | |
| AR046831A1 (es) | Compuestos de pirazolilo e imidazolilo biciclicos y usos de los mismos | |
| UY26780A1 (es) | Cicloalquil avb3 antagonistas | |
| HRP20080227T3 (hr) | Pirolidinski derivati kao ligandi histaminskih receptora | |
| ES2195933T3 (es) | Nuevos derivados de flavonas, xantonas y cumarinas. | |
| MX2019007684A (es) | Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. | |
| ES2476422T3 (es) | Compuestos de piperidina 3,5-sustituida como inhibidores de renina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |